132 related articles for article (PubMed ID: 38850717)
41. CDK4/6 Alters TBK1 Phosphorylation to Inhibit the STING Signaling Pathway in Prostate Cancer.
Li W; Guo F; Zeng R; Liang H; Wang Y; Xiong W; Wu H; Yang C; Jin X
Cancer Res; 2024 Jun; ():. PubMed ID: 38861362
[TBL] [Abstract][Full Text] [Related]
42. Photochemically controlled activation of STING by CAIX-targeting photocaged agonists to suppress tumor cell growth.
Ding C; Du M; Xiong Z; Wang X; Li H; He E; Li H; Dang Y; Lu Q; Li S; Xiao R; Xu Z; Jing L; Deng L; Wang X; Geng M; Xie Z; Zhang A
Chem Sci; 2023 Jun; 14(22):5956-5964. PubMed ID: 37293644
[TBL] [Abstract][Full Text] [Related]
43. The Development of STING Agonists and Emerging Results as a Cancer Immunotherapy.
Hines JB; Kacew AJ; Sweis RF
Curr Oncol Rep; 2023 Mar; 25(3):189-199. PubMed ID: 36705879
[TBL] [Abstract][Full Text] [Related]
44. Anti-tumor immunity by transcriptional synergy between TLR9 and STING activation.
Temizoz B; Hioki K; Kobari S; Jounai N; Kusakabe T; Lee MSJ; Coban C; Kuroda E; Ishii KJ
Int Immunol; 2022 Jul; 34(7):353-364. PubMed ID: 35419609
[TBL] [Abstract][Full Text] [Related]
45. Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity.
Lemos H; Ou R; McCardle C; Lin Y; Calver J; Minett J; Chadli A; Huang L; Mellor AL
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32847988
[TBL] [Abstract][Full Text] [Related]
46. Chitosan-based nano-micelles for potential anti-tumor immunotherapy: Synergistic effect of cGAS-STING signaling pathway activation and tumor antigen absorption.
Zhang S; Zeng Y; Wang K; Song G; Yu Y; Meng T; Yuan H; Hu F
Carbohydr Polym; 2023 Dec; 321():121346. PubMed ID: 37739513
[TBL] [Abstract][Full Text] [Related]
47. cGAS-STING Pathway as the Target of Immunotherapy for Lung Cancer.
Dan Q; Yang Y; Ge H
Curr Cancer Drug Targets; 2023; 23(5):354-362. PubMed ID: 36380440
[TBL] [Abstract][Full Text] [Related]
48. Cancer Immunotherapy Based on Cell Membrane-Coated Nanocomposites Augmenting cGAS/STING Activation by Efferocytosis Blockade.
Chen Z; Li Z; Huang H; Shen G; Ren Y; Mao X; Wang L; Li Z; Wang W; Li G; Zhao B; Guo W; Hu Y
Small; 2023 Oct; 19(43):e2302758. PubMed ID: 37381095
[TBL] [Abstract][Full Text] [Related]
49. Systemic Delivery of a STING Agonist-Loaded Positively Charged Liposome Selectively Targets Tumor Immune Microenvironment and Suppresses Tumor Angiogenesis.
Go EJ; Yang H; Park W; Lee SJ; Han JH; Kong SJ; Lee WS; Han DK; Chon HJ; Kim C
Small; 2023 Oct; 19(43):e2300544. PubMed ID: 37381624
[TBL] [Abstract][Full Text] [Related]
50. Activation of STING inhibits cervical cancer tumor growth through enhancing the anti-tumor immune response.
Shi F; Su J; Wang J; Liu Z; Wang T
Mol Cell Biochem; 2021 Feb; 476(2):1015-1024. PubMed ID: 33141310
[TBL] [Abstract][Full Text] [Related]
51. Amplifying STING activation by bioinspired nanomedicine for targeted chemo- and immunotherapy of acute myeloid leukemia.
Wang X; Huang R; Wu W; Xiong J; Wen Q; Zeng Y; Chen T; Li J; Zhang C; Zhong JF; Yang S; Zhang X
Acta Biomater; 2023 Feb; 157():381-394. PubMed ID: 36375786
[TBL] [Abstract][Full Text] [Related]
52. Structure-Activity relationship study of benzothiophene oxobutanoic acid analogues leading to novel stimulator of interferon gene (STING) agonists.
Shen A; Li X; Zhang Y; Ma J; Xiao R; Wang X; Song Z; Liu Z; Geng M; Zhang A; Xie Z; Ding C
Eur J Med Chem; 2022 Nov; 241():114627. PubMed ID: 35963129
[TBL] [Abstract][Full Text] [Related]
53. STING-Activating Polymer-Drug Conjugates for Cancer Immunotherapy.
Sheehy TL; Kwiatkowski AJ; Arora K; Kimmel BR; Schulman JA; Gibson-Corley K; Wilson JT
bioRxiv; 2024 Apr; ():. PubMed ID: 38585879
[TBL] [Abstract][Full Text] [Related]
54. Bioactivable STING Nanoagonists to Synergize NIR-II Mild Photothermal Therapy Primed Robust and Long-Term Anticancer Immunity.
Ma W; Sun R; Tang L; Li Z; Lin L; Mai Z; Chen G; Yu Z
Adv Mater; 2023 Nov; 35(48):e2303149. PubMed ID: 37691545
[TBL] [Abstract][Full Text] [Related]
55. Tumor-targeted delivery of a STING agonist improvescancer immunotherapy.
Wu YT; Fang Y; Wei Q; Shi H; Tan H; Deng Y; Zeng Z; Qiu J; Chen C; Sun L; Chen ZJ
Proc Natl Acad Sci U S A; 2022 Dec; 119(49):e2214278119. PubMed ID: 36442099
[TBL] [Abstract][Full Text] [Related]
56. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.
Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z
Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553
[TBL] [Abstract][Full Text] [Related]
57. Ectopic expression of cGAS in
Waanders L; van der Donk LEH; Ates LS; Maaskant J; van Hamme JL; Eldering E; van Bruggen JAC; Rietveld JM; Bitter W; Geijtenbeek TBH; Kuijl CP
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37072345
[TBL] [Abstract][Full Text] [Related]
58. Targeting STING for cancer immunotherapy: From mechanisms to translation.
Huang R; Ning Q; Zhao J; Zhao X; Zeng L; Yi Y; Tang S
Int Immunopharmacol; 2022 Dec; 113(Pt A):109304. PubMed ID: 36252492
[TBL] [Abstract][Full Text] [Related]
59. TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies.
Carideo Cunniff E; Sato Y; Mai D; Appleman VA; Iwasaki S; Kolev V; Matsuda A; Shi J; Mochizuki M; Yoshikawa M; Huang J; Shen L; Haridas S; Shinde V; Gemski C; Roberts ER; Ghasemi O; Bazzazi H; Menon S; Traore T; Shi P; Thelen TD; Conlon J; Abu-Yousif AO; Arendt C; Shaw MH; Okaniwa M
Cancer Res Commun; 2022 Jun; 2(6):489-502. PubMed ID: 36923556
[TBL] [Abstract][Full Text] [Related]
60. Hyperbaric oxygen facilitates teniposide-induced cGAS-STING activation to enhance the antitumor efficacy of PD-1 antibody in HCC.
Li K; Gong Y; Qiu D; Tang H; Zhang J; Yuan Z; Huang Y; Qin Y; Ye L; Yang Y
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
